Company Cabaletta Bio, Inc.

Equities

CABA

US12674W1099

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
10.19 ^USD	+2.62%		-6.68%	-55.11%

May. 15	Cabaletta Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 22	HC Wainwright Adjusts Cabaletta Bio's Price Target to $30 From $25, Maintains Buy Rating	MT

Cabaletta Bio, Inc. is a clinical-stage biotechnology company. The Company is focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). CABA-201, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Number of employees: 119

Managers	Title	Age	Since
Steven Nichtberger CEO	Chief Executive Officer	62	17-03-31
Anup Marda DFI	Director of Finance/CFO	46	18-12-31
Heather Harte-Hall CMP	Compliance Officer	-	19-02-28
Samik Basu CTO	Chief Tech/Sci/R&D Officer	-	19-11-30
David Chang CTO	Chief Tech/Sci/R&D Officer	61	19-05-31
Gwendolyn Binder-Scholl CTO	Chief Tech/Sci/R&D Officer	49	19-01-31
Martha O'Connor HRO	Human Resources Officer	-	19-02-28
Arun Das PRN	Corporate Officer/Principal	34	19-06-30
Michael Gerard LAW	General Counsel	44	21-09-06

Members of the board	Title	Age	Since
Richard Henriques BRD	Director/Board Member	68	19-02-18
Steven Nichtberger CEO	Chief Executive Officer	62	17-03-31
Mark Simon BRD	Director/Board Member	62	18-09-30
Shawn Tomasello BRD	Director/Board Member	65	23-07-20
Scott Brun BRD	Director/Board Member	56	21-06-23
Catherine Bollard BRD	Director/Board Member	56	19-04-01

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	48,276,522	45,046,235 ( 93.31 %)	0	93.31 %

Name	Equities	%	Valuation
BlackRock Advisors LLC 7.987 %	3,855,845	7.987 %	47 M $
STATE STREET CORPORATION 7.750 %	3,741,460	7.750 %	46 M $
Jennison Associates LLC 7.090 %	3,422,984	7.090 %	42 M $
Fred Alger Management LLC (13f Subfiler) 6.443 %	3,110,314	6.443 %	38 M $
Adage Capital Partners GP LLC 6.290 %	3,036,645	6.290 %	37 M $
T. Rowe Price Investment Management, Inc. 5.117 %	2,470,493	5.117 %	30 M $
Vanguard Fiduciary Trust Co. 4.715 %	2,276,222	4.715 %	28 M $
Lynx1 Capital Management LP 4.315 %	2,082,973	4.315 %	25 M $
Perceptive Advisors LLC 3.556 %	1,716,660	3.556 %	21 M $
Bain Capital Life Sciences LP 3.350 %	1,617,364	3.350 %	20 M $

Cabaletta Bio, Inc.

2929 Arch Street Suite 600

19104, Philadelphia

http://www.cabalettabio.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.19 USD

Average target price

33.56 USD

Spread / Average Target

+229.30%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
CABALETTA BIO, INC.	-55.11%	492M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs